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programmes, as many potential therapeutic drug candidates have poor BBB permeation.
Difficulties associated with the availability of human brain tissue, coupled with the time and
cost associated with using animals for this kind of research have led to the development of non-
human cell culture models. However, most BBB models display a low transendothelial electrical
resistance (TEER), which is a measure of the tightness of the BBB. To address these issues we
have established and optimised a robust, simple to use in vitro BBB model using porcine brain
endothelial cells (PBECs). The PBEC model gives high TEER without the need for co-culture with
astrocytes (up to 1300 O cm2 with a mean TEER of 800 O cm2) with well organised tight
junctions as shown by immunostaining for occludin and claudin-5. Functional assays
confirmed the presence of high levels of alkaline phosphatase (ALP), and presence of the efflux
transporter, P-glycoprotein (P-gp, ABCB1). Presence of the breast cancer resistance protein (BCRP,
ABCG2) was confirmed by TaqMan real-time RT-PCR assay. Real-time RT-PCR assays for BCRP,
occludin and claudin-5 demonstrated no significant differences between batches of PBECs, and
also between primary and passage 1 PBECs. A permeability screen of 10 compounds demon-
strated the usefulness of the model as a tool for drug permeability studies. Qualitative and
quantitative results from this study confirm that this in vitro porcine BBB model is reliable and
robust; it is also simpler to generate than most other BBB models.
This article is part of a Special Issue entitled Electrical Synapses.
& 2012 Elsevier B.V. Open access under CC BY license.57
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The blood–brain barrier is formed by brain endothelial cells
lining cerebral microvessels, and performs a combination of
physical, transport and enzymatic barrier functions (Abbott
et al., 2010). The physical barrier is largely the result of
extremely tight zonulae occludentes (tight junctions), which
seriously restrict the paracellular flux of small hydrophilic
molecules (Tsukita et al., 2001; Wolburg and Lippoldt, 2002).
The transport barrier results from a combination of specific
membrane carrier systems for uptake and efflux that regulate
small molecular traffic at apical (luminal) and basal (ablum-
inal) membranes (Begley, 2004; Hawkins et al., 2002; Hawkins
et al., 2006), together with receptor-mediated and absorptive-
mediated transcytosis (RMT, AMT) that mediate the transfer
of small amounts of larger molecules such as peptides and
proteins (Herve´ et al., 2008; Wolburg et al., 2009). The enzy-
matic barrier results from the presence on and within brain
endothelial, of ecto- and endo-enzymes capable of metabo-
lising endogenous and exogenous compounds (Abbott et al.,
2006; Persidsky et al., 2006). The net result of all three barrier
functions is protection of the brain from potentially toxic or
neuroactive agents capable of disturbing neural function,
and a contribution to homoeostatic regulation of the brain
microenvironment that is essential for neural activity and
integration.
Increased understanding of BBB function has come from
careful study in vivo, traditionally using animal models, and
increasingly involving minimally invasive investigation,
where the technologies allow, in human subjects (Hawkins
and Egleton, 2007; Rebeles et al., 2006). However, for elucidat-
ing the detailed cellular and molecular mechanisms involved,
in vitro models play an important part. A number of cell
culture models of the BBB have been developed from a variety
of species (de Boer and Gaillard, 2002; Deli et al., 2005; Garberg
et al., 2005; Gumbleton and Audus, 2001; Reichel et al., 2003).
Although the aim in many cases is to understand the human
condition, for the present, human brain endothelial models
of sufficient yield, tightness and reproducibility have not
been available. Several immortalised human BBB models
have been developed with good expression of BBB markers
but generally have a lower transendothelial electrical resis-
tance (TEER) than most animal models (Fo¨rster et al., 2008;
Grab et al., 2004; Sano et al., 2010; Weksler et al., 2005).
Models derived from rat provide useful comparison with
in vivo studies, the rat still being the most widely used animal
model for experimental study, including for pharmaceutical
applications and pharmacokinetic investigation (Abbott et al.,
1992; Perri ere et al., 2005; Perri ere et al., 2007; Roux and
Couraud, 2005). Mouse models are opening up the field for
applications using genetically modified animals (Fo¨rster
et al., 2005; Omidi et al., 2003; Shayan et al., 2011). However,
models from rat and mouse are labour-intensive and low
yield, so that for higher yield applications including medium-
throughput screening studies, bovine and porcine brain
endothelium have been the models of choice (Bowman
et al., 1983; Cecchelli et al., 1999; Franke et al., 2000;
Gaillard et al., 2001; Miller et al., 1992; Smith et al., 2007;
Zhang et al., 2006).We recently adopted a porcine brain endothelial cell (PBEC)
model first developed at Eisai Laboratories (London) by Dr.
Louise Morgan and colleagues, based on a successful earlier
bovine brain endothelial cell model (Rubin et al., 1991). A
feature of this method of cell preparation is the two-stage
filtration using nylon meshes that catch the microvessels,
followed by a subculturing step that improves purity. In the
earlier development of the method, optimal BBB phenotype and
barrier tightness were achieved by growth in supplemented
medium, including astrocyte-conditioned medium. We have
made further modifications to the method, making it signifi-
cantly simpler to prepare (by avoiding the use of astrocytes or
astrocyte-conditioned medium) and by eliminating contaminat-
ing cells such as pericytes. Here we describe important features
of the model, especially high TEER and retention of other key
BBB features, and outline applications including use as a tool
for drug screening. A report on use of a variant of the model to
examine receptor-mediated transport of interleukin-1b has
been published (Skinner et al., 2009).2. Results
2.1. Cell growth and morphology
Isolated porcine brain endothelial microvessel fragments
attached to culture flasks coated with collagen/fibronectin
within a few hours of plating. PBECs started growing out of
these microvessel fragments in clusters and became 70–80%
confluent after three days in culture (Fig. 1). Contaminating
cells such as pericytes and astrocytes were not observed in
the porcine brain endothelial cell monolayers under phase-
contrast microscope following the use of puromycin to purify
the cultures. Confluent monocultures of porcine brain
endothelial cells have an elongated cobblestone-shaped mor-
phology, although not generally so clearly spindle-shaped as
reported for rat and bovine brain endothelial cell cultures.
2.2. Tight junction proteins and paracellular barrier
Cultures of passage 1 (P.1) PBECs formed confluent mono-
layers of non-overlapping contact-inhibited cells. Immuno-
cytochemical studies revealed clear marginal staining for
occludin and claudin-5 (Fig. 2 A and B respectively) consistent
with well-organised tight junctions, characteristic of the BBB.
Clear staining for occludin and claudin-5 (Fig. 2, C and D
respectively) was also seen in freshly isolated porcine brain
microvessels.
P.1 PBECs from the ‘60s’ fraction gave higher TEER than the
‘150s’ fraction (Fig. 3) and were used for all experiments
described here. P.1 PBECs (60s) cultured on Transwell Clear
inserts were found to give a maximum TEER of 1300 O cm2
(mean¼789718 O cm2, n¼91 inserts in 24 independent
experiments and a minimum apparent permeability (Papp)
to [14C]sucrose of 3.0106 cm/s (mean¼6.0770.32106
cm/s, n¼29 inserts in four independent experiments). The
quality control (QC) benchmark for permeability was set at a
TEER of 500 O cm2 and a Papp sucrose of 8106 cm/s. P.1
PBECs always achieved these targets when the strict pre-
parative methodology was followed, including following
Fig. 1 – Phase contrast images of a primary porcine brain endothelial cell (PBEC) culture. The cells were treated with 4 lg/ml
puromycin for three days to remove contaminating cells (as described in Section 4.3). Porcine brain endothelial cells start to
migrate from microvessel fragments from day 1. By day 3, the culture is about 70% confluent and can be passaged at this
stage. Bottom right image shows confluent P.1 PBEC cultures on Transwell inserts, three days after passaging (six days from
thawing). Scale bar: 50 lm.
Fig. 2 – Fluorescence micrograph of the immunocytochemical localisation of occludin and claudin-5 in P.1 PBEC and porcine
brain microvessels. P.1 PBEC were grown on glass cover slips (A, B) then stained for tight-junction proteins occludin (A, scale
bar: 50 lm) and claudin-5 (B, scale bar: 20 lm). Porcine brain microvessels were isolated from fresh porcine brain tissue onto
glass coverslips using the ‘tissue print’ method (Section 4.5). (C) Occludin (viewed at 40magnification); (D) claudin-5
(20magnification); nuclei counterstained with Hoescht 33258.
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Table 1 – Quality control panel used to assess porcine
brain endothelial cells.
Feature Quality control benchmark
Morphology/
confluence
Pure endothelial cells/ready for experiments
within seven days of thawing
Differentiation Expression of major BBB transporters and
enzymes
Permeability TEER4500 O cm2 and Papp to [
14C]sucrose
o8106 cm/s
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Fig. 3 – TEER differences between 60s and 150s fractions
from the same batch of PBEC. Puromycin-treated PBEC were
passaged and grown on 12mm diameter Transwell Clear
filter inserts (0.4 lm pore size) for three days. Cells were
treated with supplements (CPT-cAMP, RO-20-1724 and
hydrocortisone) for 24 h and TEER measured. TEER of a
‘blank’ cell-free insert has been subtracted from all values.
Mean7SEM (n¼6).
Fig. 4 – mRNA expression of breast cancer-resistance protein
mRNA expression levels of BCRP, occludin and claudin-5 for P.1
normalised against GAPDH (mean7SEM, n¼12; independent-s
the three genes was determined by one-way ANOVA, followed
Absolute mRNA expression levels of GAPDH and BCRP. mRNA t
sample t-test; po0.01).
b r a i n r e s e a r c h 1 5 2 1 ( 2 0 1 3 ) 1 – 1 54the QC benchmarks for morphology and confluence level
(Table 1).
TaqMan real-time RT-PCR analysis confirmed the expres-
sion of occludin and claudin-5 in P.1 PBECs. When normalised
against GAPDH, mRNA expression level was significantly
higher for claudin-5 than for occludin (Fig. 4A).2.3. BBB transporters and alkaline phosphatase
2.3.1. P-glycoprotein
P-glycoprotein (P-gp, ABCB1) is an efflux transporter located
on the luminal membrane of the endothelial cells of the BBB.
Uptake of [3H]colchicine, a P-gp substrate, into confluent P.1
PBECs is shown in Fig. 5. Addition of 50 mM P-gp inhibitor(BCRP), occludin and claudin-5 in P.1 PBEC. (A) Normalised
PBEC cultures. P.1 PBEC mRNA data for each gene were
ample t-test; po0.0001). Statistical significance between
by Dunnet’s test for equal variances (po0.0001). (B)
ranscripts are from 12 samples (mean7SEM; independent-
Fig. 5 – Assessment of P-glycoprotein function in P.1 PBEC.
[3H]Colchicine uptake assay for P-gp activity. Mean7SEM
(n¼6). Independent-sample t-test; po0.05 compared to the
control. Colchicine uptake (Vd, volume of distribution) in
presence of P-gp inhibitor verapamil showed a ‘factor
increase’ (Vd in presence of verapamil/Vd in control) of 1.34
compared to the control without inhibitor, evidence for
presence of functional P-gp.
b r a i n r e s e a r c h 1 5 2 1 ( 2 0 1 3 ) 1 – 1 5 5verapamil to the incubation medium caused a significant
increase (po0.05) in colchicine uptake into P.1 PBECs
compared to control cells, evidence for presence of func-
tional P-gp.2.3.2. Breast cancer-resistance protein
TaqMan real-time RT-PCR assays confirmed the presence of
the efflux transporter breast cancer-resistance protein (BCRP)
in P.1 PBECs. Normalisation against GAPDH mRNA expression
levels in P.1 PBECs showed that BCRP expression is signifi-
cantly higher than occludin (po0.0001) and lower than
claudin-5 (po0.0001; Fig. 4A). The mRNA transcript level of
BCRP in P.1 PBECs was twice that of GAPDH (po0.01; Fig. 4B).R2 = 0.9646
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)2.3.3. Alkaline phosphatase
Alkaline phosphatase (ALP) activity of P.1 PBECs was mea-
sured using p-nitrophenyl phosphate (pNPP) as substrate.
Significantly higher levels (po0.0001) of ALP activity were
detected in P.1 PBECs than in an immortalised rat brain
endothelial cell line, RBE4 (Fig. 6).Fig. 6 – Comparison of ALP activity between P.1 PBEC and
P.55 RBE4 cells. ALP assay was performed on confluent cells
using pNPP as ALP substrate as described in Section 4.10.
ALP activity of P.1 PBEC was over 20 times greater than in
P.55 RBE4 cells (mean7SEM, n¼24; independent-sample t-
test; po0.0001).
Fig. 7 – Comparison of relative mRNA expression levels of BCRP,
expression levels between batches of PBEC. The results are exp
PBEC cultures (mean7SEM, n¼6). (B) Relative mRNA expression
batch. Results are expressed as ‘fold difference’ ratio between p
Statistical significance was determined by two-way ANOVA and
cultures (primary vs. passage 1) of PBECs.2.4. Maintenance of BBB features after passaging; mRNA
data
Normalised mRNA data were used to calculate ‘fold differ-
ences’ to monitor batch to batch differences. The results
showed no significant differences in mRNA expression levels
of BCRP, occludin and claudin-5 between batches of PBEC
cultures (based on 2-fold difference threshold; Fig. 7A) for all
genes assayed. Batch2/batch1 fold difference ratio was less
than 2-fold, which confirms the stability of the expression
levels of the genes between batches. Passage 1/primary fold
difference ratio was calculated to assess differences in mRNA
expression levels in PBECs in different batches. The resultsoccludin and claudin-5 in PBEC cultures. (A) Relative mRNA
ressed as ‘fold difference’ ratio between batch 2 and batch 1
levels between primary and P.1 PBEC cultures within each
assage 1 and primary PBEC cultures (mean7SEM, n¼6).
showed no significant differences between batches or
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Fig. 8 – Correlation between in vitro Papp (apical to basal
direction) for P.1 PBEC and calculated Log Poctanol. P.1 PBEC
were grown on Transwell Clear inserts and were used after
treatment with cAMP, RO-20-1724 and hydrocortisone for
24 h (n¼3 experiments, 9–12 inserts for each compound).
Permeability assays were performed as described in Section
4.8 and 4.15. Calculated Log Poctanol was obtained from http://
www.syrres.com/eSc/est_kowdemo.htm. Solute permeation:
open circles, passive; closed squares, uptake; closed
triangles, ABC-mediated efflux; open square, glutamate –
subject to both uptake and efflux, see Section 2.5.
b r a i n r e s e a r c h 1 5 2 1 ( 2 0 1 3 ) 1 – 1 56showed no significant differences in mRNA expression levels
between primary and P.1 PBEC cultures for either batch 1 or 2
(Fig. 7B) for all genes assayed. Mean P.1/primary fold differ-
ence ratio was less than 1.6, below the 2-fold difference of
mRNA expression considered significant.
2.5. Permeability screening of compounds
The plot of Papp vs. calculated Log Poctanol (Fig. 8) showed that
compounds predicted to move by passive permeation either
paracellularly or transcellularly (sucrose, naloxone, propra-
nolol, diazepam) had Papp that was a linear function of
calculated Log Poctanol, with R
2¼0.96. Leucine, taken up by
LAT-1 (large neutral amino acid carrier), and caffeine (satur-
able carrier-mediated transport mechanism) (McCall et al.,
1982) are both clear outliers above the line as predicted
(permeation 4predicted from Log P), while the four com-
pounds that are known substrates for either ATP-dependent
efflux transporters (digoxin, colchicine and vinblastine for P-
gp) or basolateral Na-dependent secondary active transport
(glutamate, substrate for excitatory amino acid transporter,
EAAT) are clear outliers below the line as predicted (permea-
tionopredicted from Log P).3. Discussion
3.1. BBB phenotype of PBEC model
We have optimised and characterised an in vitro BBB model
using PBECs that fits the requirements of a generally applicable
in vitro BBB model (Garberg et al., 2005; Prieto et al., 2004). PBECs
are readily available (with a yield of 1107 cells per brain) and
are easy to culture. Addition of puromycin to eliminate con-
taminating cells in the culture was one of the most significant
steps in the method, with other improvements such as careful
dissection of brains to remove meninges and white matter. This
led to a significant increase in TEER because of the purity of
cultures. Growth on rat-tail collagen/fibronectin gave good
adhesion and improved uniform growth to confluence. The
method generated PBECs with high TEER (up to 1300 O cm2,
with an average of 800 O cm2) which can be used reliably in
experiments. The minimum apparent permeability of the con-
fluent cell monolayers to [14C]sucrose was 3106 cm/s, with
permeability below 8106 cm/s among all porcine cultures
tested. The mean TEER in our PBEC cultures is similar to that
obtained by Franke et al., 2000 and 3–10 times higher than
reported for other porcine models when PBECs are cultured
without astrocytes or ACM (e.g. Jeliazkova-Mecheva and Bobilya,
2003; Smith et al., 2007; Zhang et al., 2006). Even when cultured
with astrocytes or ACM, some of these porcine models are
unable to achieve TEER comparable to our model. Furthermore,
permeability to [14C]sucrose in the present model is lower than
or comparable to that of other porcine models. Immunochem-
ical studies revealed clear marginal staining for occludin and
claudin-5 in P.1 PBECs and edge staining in porcine brain
microvessels, consistent with well-organised tight junctions.
Functional assays confirmed the presence of the brain efflux
transporter, P-gp and high levels of ALP activity in P.1 PBECs.
Functional ALP has been reported in RBE4 cells (Roux et al.,1994) and was increased when astrocyte-conditioned medium
(ACM) and retinoic acid were used (el Hafny et al., 1996). In our
model, ALP activity in P.1 PBECs without any astrocytic factors
was over 20 times greater than in P.55 RBE4 cells. We chose
RBE4 cells for comparison as this cell line is widely used and
well characterised, and has been used in previous studies of
ALP. The loss of activity in BBB enzymes such as ALP and
gamma glutamyl transpeptidate in primary PBECs is well
documented (Beuckmann et al., 1995; Meyer et al., 1990, 1991).
Therefore, the comparison here demonstrates the quality of the
present model, retaining ALP activity in culture even after seven
days from isolation. Raising intracellular cAMP in P.1 PBECs
could have contributed to the high level of ALP activity in our
model, as it has been shown that elevating cAMP can induce
ALP activity in brain endothelial cells (Beuckmann et al., 1995).3.2. Comparison with porcine models in the literature
Table 2 compares the basic characteristics achieved in this
model, with three others from the literature: Franke et al. (2000),
Zhang et al. (2006) and Smith et al. (2007). The selection of
which method to use may be influenced by many factors,
including the culture expertise of a group, models historically
used, and the intended applications. The properties of the
models are in many respects quite similar, adding to evidence
that whatever the details of the preparative method, the
confluent porcine brain endothelial model shows generally
comparable behaviour, so that results from different studies
can to some extent be pooled to form a growing database of
information. Several methods have been described, but intra-
batch and batch-to-batch variation was still a problem with
many of them (Franke et al., 2000; Zhang et al., 2006). There was
some variability in the effects of adding serum, reported to
either increase or decrease permeability (Nitz et al., 2003).
The strengths of the present model are that it is relatively
simple, involving fewer preparative steps: simply dissect out
grey matter, homogenise, filter and digest to obtain brain
microvessels. There are no complicated gradient separations.
The model reliably gives tight brain endothelial cell mono-
layers without astrocyte influence. This can be attributed to
the simple but strict preparative methodology, the removal of
contaminating cells such as pericytes through the use of
puromycin in the first three days of culture and the use of the
differentiation medium. The high TEER itself has many
advantages. It indicates good functional tight junctions,
known to help in development of good apical-basal polarity
in the cells (‘fence’ function of tight junctions, Abbott et al.,
2006) and hence in preserving many important polarised
features of the physiological BBB phenotype. Moreover, by
restricting paracellular permeation, the effective tight junc-
tions also give better resolution and discrimination for
carrier-mediated transport (‘gate’ function of tight junctions,
Abbott et al., 2006). Use of the different filter meshes to
separate the two microvessel fractions gives the option of
using the 60s for investigations such as drug permeability
assays where a tight monolayer is essential and the 150s for
uptake and efflux studies when maximum tightness is not
required. Finally, a QC test was adopted to check the relia-
bility and repeatability of different cultures.
Table 2 – Comparison of methods and barrier characteristics of selected porcine blood–brain barrier models.
Porcine BBB
model
Patabendige et al.
(this paper)
Franke et al. (2000) Zhang et al. (2006) Smith et al. (2007)
Based on Rubin et al. (1991) Bowman et al. (1983) Miller et al. (1992) Franke et al. (2000)
Meninges Remove including
into sulci
Flame, remove with surface
vessels
Remove, with surface vessels –
Grey matter
(GM)/white
matter (WM)
Cut/pinch off and
discard as much WM
as possible
GMþWM, minced Collect GM by aspiration Remove WM and
accessory organs
Homogeniser Y N, mince with blades Y by sequential filtration N, mechanically mill
Filtration mesh
size
Fine: 150 mm, 60 mm 180 mm Coarse: 1000 mm, 710 mm –
Enzyme digest 1 Collagenase, trypsin,
DNase I 1 h, 37 1C
Dispase II 2 h, 37 1C 12.5% dispase 3 h. Centrifuge
1570g, 10 min, 37 1C
1% dispase 2 h
Gradient
separation 1
– Dextran, 6800 g, 10 min, 4 1C 13% dextran, 9170 g, 10 30% Percoll, 6800 g
Enzyme digest 2 – Collagenase/dispase 0.1%
1 h 37 1C
Collagenase/dispase 0.52%
3.5 h, 37 1C
Collagenase/dispase 0.2%
1 h
Gradient
separation 2
– Percoll 1250 g Percoll 1700 g 10 min Percoll 1250 g
Yield/cells per
brain
10 106 450 cm2 flask area 10 106 25106
Medium DMEMþ10% BPDS M199þ10% ox serum MEM: F12 þ10% horse serum. M199þ10% horse serum
Subculture Y, day 3 to purify Y, day 3 to purify N N
Endothelial cell
purification
method
4 mg/ml Puromycin – – –
Switch
(differentiation)
medium
DMEMþ550 nM
HCþCPT-cAMPþRO-
20-1724 24 h. No
BPDS
1:1 DMEM: F12, Serum-free
or þ1% ox serum, þ2.5%
BSA. 550 nM HC 24 h
– M199þ550 nM HC 24 h. No
FCS
Astrocytes N N 7 ACM abluminal þC6 glioma cells or C6 CM
Filter inserts for
cell growth
12 mm diam (area
1.13 cm2)
24 mm diam (area 4.5 cm2) 24 mm diam (area 4.5 cm2) 6.5 mm and 24 mm diam
(area 0.33 cm2 and
4.5 cm2)
Filter coating Lab-made rat tail
collagen/fibronectin
Rat tail collagen (Bornstein),
dried
Rat tail collagen/fibronectin Rat tail collagen type I
Seeding density
on inserts
1 105 cells/cm2 3 104 cells/cm2 7.5 104 cells/cm2 1105 cells/cm2
Days to
confluence on
filters
3þ2/3þ1 d (switch
medium )
3þ3þ1 d (switch medium) 5–6 d 6þ1d (switch medium)
Maximum
tightness
6–8 d 7–8 d 5–9 d 7 d
TEER Endohm.
789718 O cm2 (with
puromycin)
Endohm. 4007100 to
7007100 O cm2.
Endohm. Use 4300 O cm2.
With rat ACM: TEER increase
10–25% 6–9 d.
80 O cm2 (w/o C6);
409 O cm2 (C6 CM);
834 O cm2 (C6 co)
Papp sucrose 6 106 cm/s 4.5 106 cm/s(þSerum),
1 106 cm/s(Serum).
80 106 cm/s 12.1 106 cm/s(w/o C6);
8.8 106 cm/s(C6 CM);
1.6 106 cm/s(C6 co)
Freezing
method for
long-term
storage
FCSþ10% DMSO – MEM:F12 þ10% DMSO, 20%
horse serum, heparin,
gentamycin, amphotericin
M199þ20% horse
serumþ10% DMSO
Abbreviations: yes, Y; no, N; Dulbecco’s modified Eagle’s medium, DMEM; medium 199, M199; minimum essential medium, MEM; Ham’s F12
medium, F12; hydrocortisone, HC; bovine plasma-derived serum, BPDS; bovine serum albumin, BSA; foetal calf serum, FCS; dimethyl
sulfoxide, DMSO; astrocyte-conditioned medium, ACM; conditioned medium, CM; without, w/o; transendothelial electrical resistance, TEER.
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hydrocortisone
Several studies have shown that increasing intracellular
cAMP levels (Deli et al., 2005; Gaillard et al., 2001; Hurst and
Clark, 1998; Ishizaki et al., 2003; Perri ere et al., 2007; Rubinet al., 1991) and addition of physiological levels of hydro-
cortisone (Fo¨rster et al., 2005; Hoheisel et al., 1998; Perri ere
et al., 2007) to brain endothelial cell cultures can increase the
barrier function of tight junction proteins. Ishizaki et al.
(2003) showed that cAMP increased claudin-5 gene expres-
sion via a protein kinase A (PKA)-independent pathway, but
b r a i n r e s e a r c h 1 5 2 1 ( 2 0 1 3 ) 1 – 1 58increased TEER via both PKA-dependent and -independent
pathways in PBECs. By contrast, cAMP decreased TEER in a rat
lung endothelial cell line expressing doxycycline-inducible
wild-type claudin-5 (Soma et al., 2004). The authors sug-
gested that cAMP could be responsible for increasing the
barrier function of other tight junction proteins, but not
claudin-5. However, this study was on a lung endothelial cell
line and may not be comparable to claudin-5 function in
brain endothelial cells.
Hydrocortisone is a glucocorticoid and like cAMP can
increase TEER of brain endothelial cells at physiological
concentrations (70–550 nM). Studies by Fo¨rster et al. (2005)
have shown that treatment of cEND (an immortalised mouse
brain endothelial cell line) with hydrocortisone led to an
increase in TEER by threefold and up-regulation of occludin.
A three-fold increase in TEER and over twofold increase in
expression of occludin and claudin-5 was also observed in
hCMEC/D3, immortalised human brain microvascular
endothelial cells, treated with hydrocortisone (Fo¨rster et al.,
2008). The culture medium for our in vitro PBEC model is
supplemented with 550 nM hydrocortisone and the cells are
treated with 250 mM pCPT-cAMP and 17.5 mM RO-20-1724 to
increase intracellular cAMP levels. Therefore, high TEER, ALP
activity and clear expression of tight junction proteins in our
model could also be attributed to these treatments. The
differentiation medium is replaced by a simpler medium
(‘donor buffer’) containing DMEMþ25 mM HEPES and 0.1%
bovine serum albumin without the differentiating factors for
permeability assays. These assays are of short duration
(30 min) and therefore the lack of differentiation factors does
not significantly affect the resolution of drug permeation
across the PBEC monolayer. In a different PBEC model, Nitz
et al. (2003) reported that serum-derived factors destabilised
tight junction protein strands after tight junctions were
established. The present model also avoids using serum after
tight junctions are stabilised. Monocultured PBECs in this
model are flat cells with a broadly elongate cobblestone-
shaped morphology. The more cobblestone morphology
could be an effect of hydrocortisone treatment as suggested
by Fo¨rster et al. (2005) or reflect the absence in monoculture
of soluble factors released by astrocytes that influence the
in vivo morphology of the BBB.
3.4. Inductive influence of astrocytes
Brain capillary endothelial cells in vivo are closely associated
with several cell types within the neurovascular unit (Abbott
et al., 2006) including pericytes (Daneman et al., 2010; Lai and
Kuo, 2005), astrocytes (Abbott, 2002; Abbott et al., 2006), peri-
vascular macrophages (Zenker et al., 2003) and neurons
(Schiera, 2003). Numerous studies have shown that each of
these cell types can induce aspects of BBB phenotype when co-
cultured with brain endothelial cells, with induction by astro-
cytes being the most fully documented, and astrocytes the most
common cell type used to induce BBB features in co-cultured
in vitro BBB models (Abbott et al., 2006). However, it was not
clear which cell type exerts the strongest influence in vivo, or
how BBB induction occurs during CNS development.
Recent studies using a combination of genetically engi-
neered animals and cell culture have provided a clearerdevelopmental sequence, showing initial BBB induction by
neural progenitor cells at the time of vascular ingrowth into
the neural tube (angiogenesis), followed by progressive
maturation of the BBB phenotype involving influences
first from pericytes and later from astrocytes (Armulik
et al., 2010; Daneman et al., 2010; Paolinelli et al., 2011;
Thanabalasundaram et al., 2011). Pericytes cause upregula-
tion of key BBB features such as tight junction protein
expression and organisation, and expression of nutrient
transporters such as Glut-1/SLC2A1, while downregulating
‘default’ features characteristic of peripheral endothelial cells
such as leucocyte adhesion molecule expression and vesicle
trafficking (Daneman et al., 2010). Astrocytes, which mature
later, then refine the BBB phenotype further, especially by
upregulation of efflux transporters (Daneman et al., 2010);
they also appear able to induce the expression of a greater
range of BBB-specific genes than pericytes (Nag, 2011). Both
pericytes and astrocytes are important in maintaining the
BBB phenotype in the adult (Bell et al., 2010; Nag, 2011).
When microvessels are isolated from adult brain, as typi-
cally used for in vitro BBB models, the endothelium will have a
fully functional BBB phenotype. There appear to be species
differences in the rate at which this is lost in culture,
relatively rapidly in rat and bovine brain endothelial cells,
more slowly in PBECs, as shown by the good preservation of
tight junctions, high TEER and functional efflux transporters
in monocultured PBEC models. Many studies show more
effective tight junctions and higher TEER of the tightest
in vitro models in the presence of astrocytic influence (co-
culture or conditioned medium) as demonstrated in bovine
brain endothelial cell models (Dehouck et al., 1992; Rubin
et al., 1991) and many PBEC models (Fischer et al., 2000; Kido
et al., 2002; Smith et al., 2007; Zhang et al., 2006). Earlier
studies have also shown that ALP activity is reduced in
monocultures of porcine brain endothelial cells, and co-
culturing with astrocytes is required for re-inducing the ALP
activity (Meyer et al., 1990, 1991). However, the model
described here does not require inductive influences from
astrocytes to maintain a high TEER or to show high ALP
activity. For certain more complex features such as receptor-
mediated transcytosis (RMT) (Candela et al., 2008; Demeule
et al., 2002), co-culture with astrocytes appears necessary to
sustain a sufficiently differentiated phenotype for mechan-
istic and screening studies (Cecchelli et al., 2007; Skinner
et al., 2009). While ‘triculture’ models that include pericytes
(Nakagawa et al., 2009) may show some useful additional
properties (Al Ahmad et al., 2011; Ramsauer et al., 2002),
endothelial-astrocyte models can show a BBB phenotype
close enough to the in vivo situation to make more practical
systems for mechanistic studies and permeability assays.
3.5. Extent of BBB dedifferentiation in culture
Previous studies have reported that primary brain endothelial
cells tend to lose their BBB phenotype when passaged (Franke
et al., 2000; Igarashi et al., 1999; Omidi et al., 2003; Rubin et al.,
1991). Hence changes in phenotype must be investigated not
only with respect to changes between in vivo and primary
cultures, but also between primary and passaged cultures, as
serial passaging leads to a further loss of phenotype. Another
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between cultures. Therefore, real-time PCR assays were
performed to test variability and differentiation of PBECs
when passaged once (primary to P.1) using three genes of
interest, BCRP, occludin and claudin-5. The results demon-
strated that PBECs do not dedifferentiate significantly when
passaged once, as the relative mRNA expression levels of
BCRP, occludin and claudin-5 were not significantly different
between primary and P.1 PBECs (fold difference ratio o2.0).
The immunocytochemical images from freshly isolated por-
cine brain microvessels showed clear expression of occludin
and claudin-5. Clear edge staining was also observed in P.1
PBECs, confirming the maintenance of BBB features after
passaging. The loss of in vivo phenotype reported for many
in vitro BBB models appears to be mainly due to the removal
of endothelial cells from their natural environment. However,
the changes can be counteracted to some degree using
several inductive factors and co-cultures as discussed.
3.6. PBECs as a drug screening tool
Recently developed primary cultured in vitro BBB models offer
advantages as assay systems since they express more fea-
tures of the in vivo BBB (including membrane lipid and protein
composition, expression of uptake and efflux transporters
and drug metabolising enzymes) than Caco-2 (from human
colon carcinoma) or MDCK (from canine kidney epithelium)
cell lines, which are commonly used in the pharmaceutical
industry. Until around year 2000 the in vitro BBB model
showing the best correlation with in vivo BBB permeability
was the system using bovine brain endothelial cells co-
cultured on filters above rat astrocytes (Cecchelli et al.,
1999), but over the last decade several groups have reported
successful use of porcine brain endothelial cells as useful
tools for drug screening (Franke et al., 1999, 2000; Smith et al.,
2007; Zhang et al., 2006). Our results demonstrate that the
PBEC model described here has the potential to be useful as a
permeability screen to investigate BBB permeation of drugs of
interest with a range of chemistries, including those that are
substrates for transporters, whether or not the particular
transporters involved have been identified. With inclusion of
sufficient passively permeating reference compounds, sub-
strates for transporters can be identified as outliers, for
further mechanistic study.
If required and desirable, porcine brain endothelial cell
production could be scaled up for high/medium-throughput
screening. However, it is possible to limit the numbers of
compounds that need to be tested on living BBB models using
better in silico (computer-based) screens. Thus a serial and
parallel screening process can be used to bring the numbers
to manageable level (e.g. 200 cf. 4100,000) for testing on an
in vitro BBB model (Abbott, 2004).
In conclusion, results confirm that this optimised in vitro
porcine BBB model is relatively simple to prepare, reliable and
repeatable compared to most other static BBB models, and
gives high TEER without the need for astrocyte co-culture.
The quality, simplicity and robustness of the porcine BBB
model make it an attractive model for industry to use in CNS
drug discovery programmes and also for a variety of basic
scientific projects. Because the method generates PBECs withhigh TEER, it is likely to show good apical: basal differentia-
tion for other important BBB features, including receptors,
transporters, enzymes and ion channels. It is therefore likely
to be suitable for a range of experimental projects where such
apical: basal polarity is critical, especially for vectorial trans-
port, and differences in cell signalling to and from the
endothelium that involve the apical and basal membranes.
The model is currently being optimised further to improve
the dynamic range for permeability studies, and is being used
in applications to examine several other aspects of BBB
function including transcytosis of large molecules and con-
structs, and drug efflux transporters.4. Experimental procedure
4.1. Materials
Dulbecco’s Modified Eagle’s Medium (DMEM) without phenol
red, a-MEM with Glutamax-1 and Hams F-10 with Glutamax-1
were from Invitrogen Corporation (Paisley, UK), foetal calf
serum (FCS), penicillin/streptomycin, Ca2þ/Mg2þ-free Hanks
balanced salt solution (HBSS), Ca2þ/Mg2þ-free HBSS without
phenol red, trypsin-EDTA, DMEM (for cell culture), L-15
medium, M199 medium, fibronectin, glutamine, heparin,
hydrocortisone, puromycin, verapamil, HEPES, pCPT-cAMP,
trypsin-EDTA, Ca2þ/Mg2þ-free Hanks balanced salt solution
(HBSS), Ca2þ/Mg2þ-free HBSS without phenol red, Geneticin,
basic fibroblast growth factor (bFGF), poly-L-lysine, carbodii-
mide, paraformaldehyde, Triton X-100, normal goat serum
(NGS), Hoescht 33258 nuclear stain, Sigma Fast p-nitrophenyl
phosphate (pNPP) tablets and other standard laboratory
reagents of analytical grade were from Sigma-Aldrich Che-
mical Co. (Dorset, UK). 4-(3-Butoxy-4-methoxybenzyl)-2-imi-
dazolidinone (RO-20-1724) was from Calbiochem/Merck.
Collagenase, dispase and DNase I were from Lorne Labora-
tories Ltd. (Reading, UK). Minimum Essential Medium (MEM)
was from MP Biomedicals (UK) and Bovine Plasma Derived
Serum (BPDS) was from First Link (Birmingham, UK). Nylon
meshes were obtained from Plastok associates (Wirrel, UK)
and Corning Transwell-clear inserts (12 mm diameter,
1.13 cm2 growth area, 0.4 mm pore size, 4106 pores/cm2)
were obtained from Fisher Scientific (UK). All other tissue
culture materials were obtained from Invitrogen (Paisley, UK)
unless stated otherwise. [14C]sucrose, [14C]caffeine (50 mCi/
mmol) and [3H]propranolol (30 Ci/mmol) were purchased
from GE Healthcare, UK. [3H]colchicine (76.5 Ci/mmol), [3H]
L-glutamic acid (49.9 Ci/mmol), [3H]diazepam (76 Ci/mmol),
[3H]digoxin (37 Ci/mmol), [3H]vinblastine (10.9 Ci/mmol),
[3H]naloxone (63 Ci/mmol) and OptiPhase HiSafe 2 scintilla-
tion liquid were purchased from PerkinElmer Life & Analy-
tical Sciences (Buckinghamshire, UK). [3H]L-leucine (159
Ci/mmol) was purchased from Sigma-Aldrich Ltd (Dorset,
UK). The bicinchoninic acid (BCA) protein assay kit was from
Pierce Biotechnology. Rabbit anti-occludin and rabbit anti-
claudin-5 were from Zymed laboratories and Alexa Fluor 594
labelled goat anti-rabbit secondary antibody was from
Molecular Probes. EZ1 RNA cell mini kit and QuantiTect
reverse transcription kit were from QIAGEN. All primers were
from Sigma Genosys. TaqMan probes and the 2TaqMan
b r a i n r e s e a r c h 1 5 2 1 ( 2 0 1 3 ) 1 – 1 510Universal PCR Master Mix (product number – 4304437) were
from Applied Biosystems.
4.2. Isolation of porcine brain microvessel endothelial cells
Pig brains were obtained fresh from the abattoir and trans-
ported on ice in L15 medium with added penicillin (100 U/ml)
and streptomycin (100 mg/ml). Brains were washed in phos-
phate-buffered saline (PBS) (with Caþ/Mgþ) and meninges
were thoroughly peeled off and discarded. White matter
was carefully removed. The grey matter was collected in
HEPES-buffered MEM containing 10% foetal calf serum (MEM-
H 10% FCS), forced through a 50 ml syringe to produce a
slurry, and mixed with an equal volume of MEM-H 10%.
Tissue was gently homogenised in a glass Wheaton Dounce
tissue grinder (Jencons Scientific Ltd., Leighton Buzzard, UK)
(89–127 mm clearance, 15 strokes; 25–76 mm clearance 15
strokes) and sequentially filtered, first through 150 mm nylon
mesh, then through 60 mm nylon mesh. Microvessel frag-
ments trapped on the 150 and 60 mm meshes were kept
separate and digested at 37 1C for 1 h in medium M199
containing 10% FCS, 223 U/mg collagenase, 211 U/mg trypsin
and 2108 U/mg DNase with continuous agitation. Microves-
sels were washed off the meshes with the enzyme mixture,
centrifuged for 5 min at 240g at 4 1C to remove enzyme, then
resuspended in MEM-H 10% FCS and centrifuged again; the
resulting vessel fractions were kept separate as ‘150s’ and
‘60s’, the latter giving higher TEER. The ‘60s’ were used for all
experiments described here. Digested fragments were resus-
pended in 10% DMSO in foetal calf serum, brought slowly to
80 1C and stored in liquid nitrogen. Six pig brains gave 12
1 ml aliquots of ‘60s’.
4.3. Culture of capillary fragments
Capillary fragments were thawed and resuspended in plating
medium consisting of DMEM with 10% BPDS with 100 U/ml
penicillin, 100 mg/ml streptomycin, 2 mM glutamine, 125 mg/ml
heparin, with 4 mg/ml puromycin to kill contaminating cells,
especially pericytes (Perriere et al., 2005). One aliquot was plated
into two T75 flasks coated with lab-prepared rat tail collagen
(Strom and Michalopoulos, 1982) and 7.5 mg/ml fibronectin, and
grown to 70–80% confluence. Cells were detached by brief
trypsinisation (500 BAEE units trypsin and 0.47 mM EDTA.4Na
in HBSS without Ca2þ or Mg2þ), then centrifuged at 360g for
5 min. The pellet of these first passage (P1) cells was resus-
pended in plating medium containing DMEM, 10% BPDS, 100 U/
ml penicillin, 100 mg/ml streptomycin, 2 mM glutamine and
125 mg/ml heparin. Cells were seeded onto collagen/fibronectin
coated Transwell-Clear inserts at a density of 1105 cells/cm2
or at 1104 cells/well in 96-well plates for functional studies
and grown for 2–3 day until confluent. The medium was
changed to serum-free medium supplemented with 550 nM
hydrocortisone (Hoheisel et al., 1998) and the cells were treated
with 250 mM pCPT-cAMP and 17.5 mM RO-20-1724 (Rubin et al.,
1991); these supplements helped to improve differentiation of
BBB properties, especially tight junction maturation (Fo¨rster
et al., 2005). PBECs were used in experiments 24 h after this
medium change. The quality of the model in terms of cell
growth was assessed according to the time the cultures took tobecome confluent. The quality control (QC) benchmark was
three days to become 70–80% confluent after first plating and
another three days to become 100% confluent after passaging.
All the cultures assessed passed this QC test (Table 1) and were
suitable for use in subsequent experiments.
4.4. RBE4 immortalised rat brain endothelial cell culture
RBE4 cells (Roux et al., 1994) were kindly provided by Dr. P.O.
Couraud and Dr. F. Roux (Inserm, Paris). RBE4 cells were
maintained in a-MEM with Glutamax-1 (45%), Hams F-10
with Glutamax-1 (45%) containing 10% FCS, Geneticin
(300 mg/ml) and basic fibroblast growth factor (bFGF, 1 ng/
ml). Cells were grown in collagen-coated T25 flasks and were
maintained in 5% CO2 humidified atmosphere at 37 1C. The
cells were passaged every three day and the culture medium
replaced every 2–3 days. RBE4 were seeded at 1.0104 cells/
200 ml growth medium per well in 96-well plates and grown to
confluence. Experiments were performed when cells were
confluent, typically within three days of seeding.
4.5. Tissue print method for porcine brain microvessels
A tissue print method was used to attach porcine brain
microvessels to glass slides by modifying a technique for
attaching rat retinal microvessels to glass coverslips
(Sakagami et al., 1999). A small piece of fresh porcine brain
was placed in a Petri dish containing 2 ml medium. Using
forceps and a scalpel, the brain matter was cut into 1–2 mm3
pieces, and then a cut piece was placed on a poly-L-lysine -
coated glass slide. A second glass slide, also coated with poly-
L-lysine was placed over the piece of brain tissue. Forceps
touching the upper side provided gentle downward pressure
that sandwiched the piece of brain tissue between the two
glass slides. During this tissue print step, microvessels adhere
to the glass slides. After 1 min, the upper glass slide was
carefully removed. The two slides were placed in a Coplin jar
filled with PBS to wash off excess tissue. The tissue prints
were further processed for immunocytochemistry.
4.6. Immunochemistry
P.1 PBECs were grown on glass coverslips coated with col-
lagen/carbodiimide to aid cell adhesion (Nobles and Abbott,
1994). P.1 PBECs or porcine brain microvessels were washed
with PBS, fixed with 3% paraformaldehyde for 45 min and
then permeabilised in 0.1% Triton X-100. To block non-
specific binding, cells/microvessels were treated for 60 min
with normal goat serum and incubated overnight at 4 1C with
primary antibodies (rabbit anti-occludin and rabbit anti-
claudin-5) diluted 1:100 in PBS containing 3% NGS. Cells/
microvessels were subsequently rinsed with PBS for 60 min
and incubated for 2 h at room temperature with secondary
Alexa Fluor 594 labelled goat anti-rabbit antibody and
Hoescht 33258 nuclear stain. Cells/microvessels were washed
again for 60 min with PBS before mounting on glass slides
using Mowiol. Samples were visualised by fluorescence
microscopy (Axioskop; Carl Zeiss Ltd.) and images were
captured by Axiovision software (Carl Zeiss Ltd.).
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TEER across PBEC monolayers on Transwells was determined
using an EVOM resistance system (World Precision Instru-
ments, Hertfordshire, UK) with Endohm electrode chamber.
The measured resistance of cells grown on Transwell filter
inserts was corrected for resistance across an empty col-
lagen/fibronectin-coated Transwell insert, and multiplied by
surface area, to give TEER in ohms cm2 (O cm2).
4.8. Apparent permeability to [14C]sucrose
Permeability assays were performed on cell monolayers with
TEER 4500 O cm2. Culture medium was aspirated and the
inserts transferred to 12-well plates containing 1.5 ml/well
donor buffer (DMEM without phenol red, 25 mM HEPES and
0.1% bovine serum albumin) and placed in an orbital shaker
at 37 1C. Donor buffer (0.5 ml) containing [14C]sucrose
(0.15 mCi/ml, specific activity 643 mCi/mmol) was added to
the inserts sequentially at 10-s intervals. At t¼5 min, the
inserts were transferred to the next well containing donor
buffer. This procedure was repeated for all inserts at t¼15
min and t¼30 min. At the end of the experiment, samples
were taken from each insert and well to scintillation vials.
OptiPhase HiSafe 2 scintillation liquid was added to each vial
and radioactivity was counted using a Canberra Packard
Tricarb 1900 TR Liquid Scintillation Analyser.
Cleared volume was calculated using the following equation
and plotted as a function of time:
Cleared volume mlð Þ ¼MRðdpmÞ=CD dpm=ml
  ð1Þ
where is the MR¼amount of radio-labelled compound in the
receiver compartment, dpm¼disintegrations per minute, CD¼
concentration of the compound in the donor compartment.
All dpm values were corrected for background dpm. The
slope of the clearance curve was obtained by linear regression
and represents the PS (i.e. permeability  surface area)
product. Apparent permeability (Papp, cm/s) was calculated
using the following equation:
Papp cm=s
 ¼ PS product cm3=s =surface area of the insert cm2 
ð2Þ
4.9. P-glycoprotein function
Colchicine uptake assay: P-gp function was measured using
uptake of [3H]colchicine (P-gp substrate) on cells grown in 24-
well plates (Begley et al., 1996). Uptake medium contained
HBSS without phenol red, 10 mM HEPES, [14C]sucrose
(0.045 mCi/ml, specific activity 0.2 mCi/mol) to correct for
non-specific binding, and [3H]colchicine (1.0 mCi/ml, specific
activity 76.5 Ci/mmol). Briefly, culture medium was aspirated
off control wells and 1ml uptake medium per well was added
at 10-s intervals to each well. This procedure was repeated for
the test wells with 50 mM verapamil (P-gp inhibitor) in the
uptake medium. Cells were incubated for 30 min at 37 1C,
then uptake medium was aspirated and cells were washed
three times with PBS. Cells were lysed with 1% Triton X-100
for 1 h and 300 ml aliquots taken for counting radioactivity.Fifty-microlitre aliquots from each uptake medium (7vera-
pamil) were taken as standards. OptiPhase HiSafe 2 scintilla-
tion liquid was added to each vial and radioactivity counted
using a Canberra Packard Tricarb 1900 TR Liquid Scintillation
Analyser. Protein concentration of a 100 ml aliquot from each
well was determined using the BCA protein assay kit. The
cellular accumulation of [3H]colchicine was calculated as the
distribution volume (Vd, ml/mg protein) derived from the ratio
of cell radioactivity/mg (dpm/mg) protein over the radio-
activity per ml uptake medium after correcting for background
radioactivity (Eq. (3)). Vd for [
3H]colchicine was corrected for
non-specific binding by subtracting the Vd for [
14C]sucrose, as
non-permeant extracellular marker.
Vd mlð Þ ¼ dpm in cells= dpm in aliquot of uptake medium

=volume of aliquot mlð Þ ð3Þ
All dpm values were corrected for background dpm. Vd was
then normalised for the cell protein concentration (mg) to
give units of ml/mg protein.4.10. Alkaline phosphatase (EC 3.1.3.1) assay
P.1 PBECs or RBE4 cells were grown in 96-well plates at
1.0104 cells/200 ml growth medium per well. Cells were
washed three times with PBS, and cell membranes disrupted
by freezing at 80 1C for 20 min. Alkaline phosphatase (ALP)
assay was performed using Sigma Fast p-nitrophenyl phos-
phate tablets. Two hundred microlitres of pNPP was added to
each well and incubated in the dark for 60 min at room
temperature. Absorbance at 405 nm was read in a Labsystems
Multiskan Ascent plate reader and protein concentration
determined using the BCA protein assay kit. ALP activity
levels are reported as absorbance per milligram protein.4.11. RNA extraction and cDNA analysis
Two vials each of PBECs from two different batches (batch 1 and
2) of PBEC were used to obtain primary and P.1 PBECs. RNA was
extracted from three primary and P.1 cultures from each vial (24
samples) using the EZ1 RNA cell mini kit. Twelve microlitres of
RNA (300–450 ng) from each sample was reverse transcribed
using the QuantiTect reverse transcription kit to generate
cDNA. RNA and cDNA were analysed (260/280 ratio: RNA2.0;
cDNA1.8) and quantified using the NanoDrops ND-1000
spectrophotometer (NanoDrop Technologies, USA).4.12. Primers and probes
Primers and TaqMans probes for porcine glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, reference gene), occludin,
claudin-5 and BCRP were designed using Primer Expresss
software from Applied Biosystems. The total gene specificity
of the nucleotide sequences chosen for the primers and
probes was confirmed using nucleotide-nucleotide BLAST
searches (GenBank database sequences) (National Center for
Biotechnology Information 2006). The nucleotide sequences
of the oligonucleotide hybridisation primers and probes for
TaqMan analysis are shown in Table 3.
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TaqMan real-time polymerase chain reaction (PCR) assays
were performed using the AB 7900HT Real-Time PCR System
with a 384-well configuration. The TaqMan probes used in
this study were dual-labelled with a 50 end 6-FAM (a high-
energy ‘Reporter’ dye) and a 30 end TAMRA (a low-energy
‘Quencher’ dye). The optimum primer and probe concentra-
tions were determined by running replicate standard samples
at different primer and probe concentrations. The PCR reac-
tion mixture contained 2 ml of cDNA sample (10 ng) and
2TaqMan Universal PCR Master Mix with 900 nM primers
and 250 nM TaqMan probe in a total volume of 20 ml. After an
initial step of AmpErases uracil-N-glycosylase activation (to
prevent the re-amplification of carryover-PCR products) at
50 1C for 2 min and denaturation at 95 1C for 10 min, the
cDNA products were amplified with 40 PCR cycles, consisting
of a denaturation step at 95 1C for 15 s and an extension step
at 60 1C for 1 min. Each cDNA sample was run in technical
triplicate using gene-specific primers. Therefore each gene
set included 36 target and 36 reference cDNA samples. Each
gene set also contained a 5-point standard curve for the
reference and target genes, a no-template control, an extrac-
tion negative and a reverse transcriptase (RT) negative as
controls.
4.14. Gene expression analysis
mRNA expression was analysed independently by one-way
analysis of variance (ANOVA) using Satistica 6 software
(StatSoft Inc., USA). Data analysis was carried out using
Sequence Detection Systems software (Applied Biosystems).
For quantification of gene expression changes, the ‘relative
standard curve method’ was used to calculate relative fold
changes normalised against the GAPDH gene (endogenous
control) using Eqs. (5) and (6). No significant differences were
observed between vials within a batch (for all genes) and the
vials behaved consistently across the two batches tested
(batch 1 and 2). Therefore, data from all vials were pooled
to increase the level of replication for each condition. Fold
differences were calculated using Eq. (7) to compare batch-to-
batch differences and primary vs. P.1 gene expression levels.
A 2-fold difference is considered significant.
Normalised targetðtestÞ NTT ¼Target=endogenous control
ð5Þ
Normalised targetðcalibratorÞ NTC ¼Target=endogenous control
ð6Þ
Fold difference in target¼NTT=NTC ð7Þ4.15. Permeability screening
Permeability assays (apical to basal direction) were performed
on 10 radio-labelled compounds covering passive permeation
([3H]diazepam, [3H]naloxone, [3H]propranolol, [14C]sucrose),
uptake ([14C]caffeine, [3H]L-glutamic acid (as Na glutamate in
saline), [3H]L-leucine) and efflux ([3H]colchicine, [3H]digoxin,
b r a i n r e s e a r c h 1 5 2 1 ( 2 0 1 3 ) 1 – 1 5 13[3H]vinblastine) transporters, as described for [14C]sucrose in
Section 4.8. The apparent permeability Papp was calculated
according to Eq. (2) and plotted against the calculated Log
Poctanol as a measure of lipophilicity of the compound. Log
Poctanol estimation was obtained from http://www.syrres.com/
eSc/est_kowdemo.htm.4.16. Statistical analysis
Data were expressed as mean7standard error of the mean
(SEM) and analysed and presented using Microsoft Excel or
GraphPad Prism (version 4.0). Groups of two were analysed
using Student’s t-test, groups of three or more were analysed
using one-way analysis of variance (ANOVA) with a Dunnett’s
post-hoc test. Values were considered to be significantly
different when the probability that differences were not due
to chance alone was less than 5% (p o0.05).Acknowledgments
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